Newsletter

Subscribe and receive updates on this company

Text STOCKS to 72727 for mobile alerts

We are excited to present Pernix Therapeutics Holdings, Inc. (NASDAQ: PTX).

Full DD Report for PTX

You must become a subscriber to view this report.


Recent News from (NASDAQ: PTX)

FDA OKs first non-opioid treatment for opioid withdrawal
The FDA approves privately held US WorldMeds LLC's Lucemyra (lofexidine hydrochloride) for the management of opioid withdrawal symptoms in adults who abruptly discontinue opioids. More news on: Endo International plc, Allergan plc, Johnson & Johnson, Healthcare stocks news, Read ...
Source: SeekingAlpha
Date: May, 16 2018 16:44
Pernix Therapeutics' (PTX) CEO John Sedor on Q1 2018 Results - Earnings Call Transcript
Pernix Therapeutics Holdings, Inc. (PTX) Q1 2018 Earnings Conference Call May 10, 2018 04:30 PM ET Executives Bob Yedid - Investor Relations John Sedor - Chairman and Chief Executive Officer George Jones - Vice President of Sales and Marketing Angus Smith - Senior Vice Presiden...
Source: SeekingAlpha
Date: May, 10 2018 18:26
Pernix Therapeutics Reports First Quarter 2018 Financial Results
MORRISTOWN, N.J., May 10, 2018 (GLOBE NEWSWIRE) -- Pernix Therapeutics Holdings, Inc. (NASDAQ:PTX), a specialty pharmaceutical company, announced today its financial results for the three months ended March 31, 2018. First Quarter 2018 Financial Highlights First quarter 2018 net r...
Source: GlobeNewswire
Date: May, 10 2018 16:01
Pernix Therapeutics to Report First Quarter 2018 Financial Results on Thursday, May 10
MORRISTOWN, N.J., May 01, 2018 (GLOBE NEWSWIRE) -- Pernix Therapeutics Holdings, Inc. (NASDAQ:PTX), a specialty pharmaceutical company, announced today that the Company will report financial results for the first quarter ended March 31, 2018, after the market close on Thursday, May 10, 2018...
Source: GlobeNewswire
Date: May, 01 2018 16:05
Pending Orexigen Sale Should Serve As Warning Sign
This week Orexigen ( OREX ) announc ed that the company has received an offer to buy out the company for a total of $75 million. The offer came from Nalpropion Pharmaceuticals and the company has entered into an agreement relating to the possible sale. Before we get to far ahead of oursel...
Source: SeekingAlpha
Date: April, 26 2018 11:08
Opioid prescriptions dropped 12% in 2017
Opioid prescriptions dropped 12% in 2017, according to a report from the IQVIA Institute for Human Data Science. More news on: Johnson & Johnson, Endo International plc, Teva Pharmaceutical Industries Limited, Healthcare stocks news, Read more ...
Source: SeekingAlpha
Date: April, 26 2018 03:18
Orexigen agrees to sell itself to Nalpropion Pharma for $75M; shares down 34%
Orexigen ( OREX ) announces that it has inked an agreement with Nalpropion Pharmaceuticals to sell virtually all of its assets for $75M in cash. More news on: Orexigen Therapeutics, Inc., Pernix Therapeutics Holdings, Inc., Healthcare stocks news, Merger & acquisition news, Stocks on...
Source: SeekingAlpha
Date: April, 23 2018 13:36
Pernix Therapeutics Announces Participation in Lead Bid for Acquisition of Worldwide Rights to Contrave® for Weight Loss
MORRISTOWN, N.J, April 23, 2018 (GLOBE NEWSWIRE) -- Pernix Therapeutics Holdings, Inc. (NASDAQ:PTX), a specialty pharmaceutical company, today announced that it has agreed to participate in an investor group (collectively with Pernix, the “Investors”) that has entered into a &...
Source: GlobeNewswire
Date: April, 23 2018 11:30
U.S. opioid prescriptions down 12% last year, largest drop in 25 years
According to IQVIA ( IQV -0.8% ), U.S. opioid prescriptions declined 12% in 2017, the largest annual drop in 25 years as doctors respond to the opioid crisis. More news on: IQVIA Holdings, Inc., Insys Therapeutics, Inc., Johnson & Johnson, Healthcare stocks news, News on ETFs, ...
Source: SeekingAlpha
Date: April, 19 2018 11:25
DEA aiming to collar production of opioids
The U.S. Drug Enforcement Administration (DEA) has unveiled plans to restrict the amount of opioids made by drug firms if it believes the medications are being diverted for illicit use. The proposed new rules were announced today in a speech by Attorney General Jeff Sessions. More news o...
Source: SeekingAlpha
Date: April, 17 2018 15:35

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-05-182.842.7452.842.6681,822
2018-05-172.682.7812.94992.67197,966
2018-05-162.672.672.682.6441,730
2018-05-152.682.622.692.552777,424
2018-05-142.632.662.692.56135,778

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-05-1818,57642,16344.0576Short
2018-05-1767,243117,98656.9924Short
2018-05-169,35930,39230.7943Cover
2018-05-1522,75941,52154.8132Short
2018-05-1440,02664,69061.8736Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on PTX.


About Pernix Therapeutics Holdings, Inc. (NASDAQ: PTX)

Logo for Pernix Therapeutics Holdings, Inc. (NASDAQ: PTX)

Not available

 

Contact Information

 

 

Current Management

  • W. Bradley Blair II / President, CEO
  • Scott D. Peters / CFO

Current Share Structure

  • Market Cap: $30,394,260 - 05/11/2018
  • Issue and Outstanding: 11,872,758 - 03/01/2018

 


Recent Filings from (NASDAQ: PTX)

Additional proxy soliciting materials - definitive
Filing Type: DEFA14AFiling Source: edgar
Filing Date: May, 11 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 10 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 10 2018
Additional proxy soliciting materials - definitive
Filing Type: DEFA14AFiling Source: edgar
Filing Date: April, 30 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: April, 24 2018
Amendment to a previously filed Form 4
Filing Type: 4/AFiling Source: edgar
Filing Date: April, 09 2018
Additional proxy soliciting materials - definitive
Filing Type: DEFA14AFiling Source: edgar
Filing Date: April, 09 2018
Official notification to shareholders of matters to be brought to a vote (Proxy)
Filing Type: DEF 14AFiling Source: edgar
Filing Date: April, 09 2018
Preliminary proxy statement providing notification matters to be brought to a vote
Filing Type: PRE 14AFiling Source: edgar
Filing Date: March, 30 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 27 2018

 

 


Daily Technical Chart for (NASDAQ: PTX)

Daily Technical Chart for (NASDAQ: PTX)


Stay tuned for daily updates and more on (NASDAQ: PTX)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: PTX)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

The Subway Trader
@TheSubwayTrader

 

 


Disclaimer: The Subway Trader publishes reports providing information on selected companies. The Subway Trader is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. The Subway Trader accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in PTX is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. The Subway Trader has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. The Subway Trader does not own any shares of PTX and does not buy, sell, or trade any shares of PTX. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by The Subway Trader. All rights reserved. Our Full Disclaimer: http://thesubwaytrader.com/disclaimer/